Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
1,406
datasets available to search
ShareScore release 0.9.0
Dataset results
1,406 results for “Migraine”
Occipital Blocks for Acute Migraine
ClinicalTrials.gov study NCT03526874. IPD Sharing: UNDECIDED. Countries: 1. Publications: 7.
Randomized Trial in Adult Participants With Acute Migraines
ClinicalTrials.gov study NCT04571060. IPD Sharing: Not stated. Countries: 1. Publications: 1.
A SLC1A3 variant associated with hemiplegic migraine and acetazolamide-responsive MRS changes
Open the record for dataset details and reuse information.
Migraine monoclonal antibodies against CGRP change brain activity depending on ligand or receptor target – an fMRI study
Open the record for dataset details and reuse information.
Data from: Gray matter volume modifications in migraine: a cross-sectional and longitudinal study
Objective. To explore cross-sectional and longitudinal gray matter (GM) volume changes in migraine patients and their association with patients' clinical characteristics and disease activity. Methods. Brain T2-weighted and 3D T1-weighted scans were acquired from 73 episodic migraineurs and 46 age- and sex-matched non-migraine controls at baseline. Twenty-four migraineurs and 25 controls agreed to be re-examined after a mean follow-up of 4 years. Using a general linear model and SPM12, a whole-brain analysis was performed to assess GM volume modifications. Results. At baseline, compared to controls, migraine patients showed lower cerebellar GM volume and higher volume of regions of the fronto-temporal lobes. At follow-up, migraineurs were significantly older than controls. Over the follow-up, migraineurs developed an increased volume of fronto-temporo-parietal regions, which was more prominent in patients with a higher baseline disease activity: long disease duration and high attack frequency. Migraineurs also developed decreased GM volume of visual areas, which was related to higher pain severity. Patients with an increased attack frequency at follow-up experienced both increased and decreased volume of nociceptive regions. In migraineurs, reduced GM volume of extrastriate visual areas during the follow-up was significantly correlated to baseline disease activity: shorter disease duration and lower attack frequency. Conclusion. In this cohort, the migraine brain changes dynamically over time and different pathophysiological mechanisms can occur in response to patients' disease severity. The interaction between predisposing brain traits and experience-dependent responses might vary across different nociceptive and visual areas, thus leading to distinct patterns of longitudinal GM volume changes.
Adrenomedullin induces migraine-like attacks in patients with migraine without aura
<p><b>Objective</b>: To determine whether the intravenous infusion of adrenomedullin, a potent vasodilator belonging to calcitonin family of peptides, provokes attacks of migraine in patients.</p> <p><b>Methods</b>: We have enlisted twenty migraine without aura patients to participate in a placebo-controlled and double-blinded clinical study. In a randomized and crossover design the patients received an intravenous infusion of human adrenomedullin (19.9 picomole/kg/min) or placebo (saline) administrated via an automated intravenous pump for period of (20 minutes). The patients participated in two study days with washout period of minimum of seven days. The main outcome of the study was predefined as a difference in migraine incidence (0–12 h).</p> <p><b>Results</b>: Eleven migraine without aura patients (55%) fulfilled migraine attacks criteria after adrenomedullin infusion in comparison to only three patients reported attack (15%) after placebo (<i>P= </i>0.039). We found that patients reported in a period of (0-12 hours) stronger headache intensity after adrenomedullin in comparison to placebo infusion (<i>P= </i>0.035).</p> <p><b>Conclusion</b>: Our data implicate adrenomedullin in migraine pathogenesis. This suggests that adrenomedullin and/or its receptors are novel therapeutic targets for the treatment of migraine. However, we cannot discount for the possibility that adrenomedullin may be acting through the canonical CGRP receptor.</p>
Appendix: Association between hemostatic profile and migraine: a Mendelian randomization analysis
<p><b>Objective: </b><span>To assess support for a causal relationship between </span>hemostatic measures and migraine susceptibility using genetic instrumental analysis.</p> <p><b>Methods: </b>Two-sample Mendelian randomization (MR) instrumental leveraging available genome-wide association study (GWAS) summary statistics was applied to hemostatic measures as potential causal for migraine and its subtypes, migraine with aura (MA) and migraine without aura (MO). Twelve blood-based measures of hemostasis were examined, including plasma level or activity of eight hemostatic factors and two <span>fibrinopeptides together with </span>two hemostasis clinical tests<span>.</span></p> <p><b>Results: </b>There were significant instrumental effects between increased coagulation factor VIII activity (FVIII, odds ratio[95% confidence interval]=1.05[1.03, 1.08]/standard deviation (SD), <i>P</i>=6.08×10<sup>-05</sup>), von Willebrand factor level (VWF, 1.05[1.03, 1.08]/SD, <i>P</i>=2.25×10<sup>-06</sup>), and phosphorylated <span>fibrinopeptide A level</span> (1.13[1.07, 1.19]/SD, <i>P</i>=5.44×10<sup>-06</sup>) with migraine susceptibility. When extended to migraine subtypes, FVIII, VWF, and phosphorylated <span>fibrinopeptide A</span> showed slightly stronger effects with MA than overall migraine. Fibrinogen level was inversely linked with MA (0.76[0.64, 0.91]/SD, <i>P</i>=2.32×10<sup>-03</sup>) but not overall migraine. None of the hemostatic factors was linked with MO. In sensitivity analysis, effects for fibrinogen and phosphorylated <span>fibrinopeptide A</span> were robust, while independent effects of FVIII and VWF could not be distinguished, and FVIIII associations were potentially affected by pleiotropy at the <i>ABO</i> locus. Causal effects from migraine to the hemostatic measures were not supported in reverse MR. However, MA was not included due to lack of instruments.</p> <p><b>Conclusions:</b> The current study supports potential causality of increased FVIII, VWF, and phosphorylated <span>fibrinopeptide A,</span> and decreased fibrinogen in migraine susceptibility, especially for MA, and may provide insights into the etiology underlying the relationship between <span>hemostasis</span> and migraine.</p>
Fig. 1 Visual hallucinations observed during auditory-visual synaesthesia. a First episode, b Second episode, c in Auditory-visual synaesthesia in a patient with basilia migraine
<p>Fig. 1 Visual hallucinations observed during auditory-visual synaesthesia. a First episode, b Second episode, c Third episode.</p>
Figure 1 in Patients profiling for Botox® (onabotulinum toxin A) treatment for migraine: a look at white matter lesions in the MRI as a potential marker
Figure 1 Coronar brain MRI slices (FLAIR), in (a), on the left side, with one WML in a responder and in (b), on the right side, with three WML in a non-responder.
A Cost-Utility Analysis of Oral Triptans for Migraine in an Adult Outpatient Setting in Japan
<p><strong><span>Objectives</span></strong><span><strong>. </strong>Pharmacoeconomic studies have not been performed frequently in Japan. This study attempted to clarify which oral triptans, including eletriptan, naratriptan, rizatriptan, sumatriptan, and zolmitrian, are cost-effective in treating migraine in an adult outpatient setting in Japan.</span></p> <p><strong><span>Methods</span></strong><span><strong>. </strong>A cost-utility analysis was conducted for healthcare payers. The population targeted was Japanese patients over the age of 18 who experienced migraines. A base-case model was prepared using probabilities from a network meta-analysis. Direct costs consisted of medical and drug costs (2017 version). Effectiveness was measured with the EQ-5D-3L questionnaire for adult patients with migraine. The duration of the study was 30 days.</span></p> <p><strong><span>Results</span></strong><span><strong>.</strong> The cost-utility analysis base-case scenario demonstrated that eletriptan, rizatriptan, and sumatriptan were cost-effective from the healthcare payers' perspective. Deterministic sensitivity analyses showed that the results were sensitive to the drug prices of three triptans. A probabilistic sensitivity analysis revealed that eletriptan, rizatriptan, and sumatriptan were acceptable because of their accessibility and the healthcare payer's willingness to pay for them (5,000,000 yen/quality-adjusted life-years) were 0.662, 0.172, and 0.075, respectively.</span></p> <p><strong><span>Conclusions</span><span>.</span> </strong><span>The results revealed that eletriptan, rizatriptan, and sumatriptan are cost-effective treat</span><span>ments</span><span> in Japan </span><span>for </span><span>migraine from a healthcare payer's perspective.</span></p>
Study on 30 Outpatients with Chronic Migraine Treated with Well-Being Therapy or with a Control Therapy
ClinicalTrials.gov study NCT03404336. IPD Sharing: NO. Countries: 1. Publications: 1.
Efficacy of a Novel App-based Migraine Treatment Platform - a Pilot Study
ClinicalTrials.gov study NCT04106505. IPD Sharing: NO. Countries: 1. Publications: 3.
Identification of Endometriosis and Migraine Criteria in Women With the Comorbidity of Both Conditions in Comparison With Women Who Only Suffer From Endometriosis - A Pilot Study
ClinicalTrials.gov study NCT04816357. IPD Sharing: NO. Countries: 1. Publications: 2.
Intranasal Cooling for Symptomatic Relief of Migraine
ClinicalTrials.gov study NCT02375789. IPD Sharing: Not stated. Countries: 1. Publications: 26.
CGRP-induced Migraine Attacks in Patients Who Have Tried Anti-CGRP Monoclonal Antibody Treatment
ClinicalTrials.gov study NCT03481400. IPD Sharing: NO. Countries: 1. Publications: 1.
Sequential, Multiple Assignment, Double Randomized Preference, Migraine Behavioral Trial
ClinicalTrials.gov study NCT06170281. IPD Sharing: YES. Countries: 1. Publications: 3.
Neurophysiology of Prophylactic Treatment in Migraine
ClinicalTrials.gov study NCT04019496. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Candesartan for Migraine Prevention:
ClinicalTrials.gov study NCT04574713. IPD Sharing: Not stated. Countries: 2. Publications: 1.
Adrenomedullin Effect on Migraine Without Patients
ClinicalTrials.gov study NCT04111484. IPD Sharing: NO. Countries: 1. Publications: 1.
Non-invasive Vagus Nerve Stimulation for the Prevention of Migraines
ClinicalTrials.gov study NCT03716505. IPD Sharing: NO. Countries: 1. Publications: 1.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.